Acute tadalafil administration increases plasma fatty acids without changes in the inflammatory response in healthy men

• Authors: Roberta Ceci , Guglielmo Duranti , Paolo Sgrò , Stefania Sabatini , Luigi Di Luigi
• Languages of publication: EN

Abstracts

EN

Purpose: Tadalafil, the phosphodiesterase type 5 inhibitor (PDE5I), has been shown to reduce visceral adipose tissue in rabbit and to improve lean mass content in non-obese men. In order to clarify this effect in humans, in the present study we determined the impact of an acute oral tadalafil administration on lipolysis by evaluating plasma free fatty acids (FFAs) and glycerol. FFAs are potential modulator of inflammation response that we evaluated through tumor necrosis factor alpha (TNFα), interleukin 6 (IL6), interleukin 8 (IL8) and interleukin 10 (IL10) plasma levels. Moreover, we determined whether the effects of tadalafil would be reflected in variation of plasma levels of cGMP and NO, two important molecules involved in PDE5Is signaling. Methods: Twelve healthy subjects were supplemented with 20 mg of tadalafil or a placebo, in a double-blind, randomized, cross-over design. Blood samples were collected immediately before, and at 2, 6, and 24 hours post ingestion, and assayed for biochemical analysis. Results: A condition effect was noted for FFAs and glycerol, with values higher for tadalafil when compared to the placebo group, at 2 and 6 hours post ingestion. No statistically significant effects were noted for glucose, cGMP, nitrate and nitrite. No inflammatory response was induced by tadalafil. Conclusion: Tadalafil, in human subjects, increases lipolysis as evidenced by a significant increase in circulating FFAs and glycerol, without affecting the plasma cGMP and NO levels; noticeably, the increase in FFAs did not develop an inflammatory response. Further well-controlled studies are warranted to assess the impact of tadalafil administration on weight/fat loss.

Keywords

EN

tadalafil; lipolysis; FFAs; cytokines; cGMP

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2017
• Volume: 64
• Issue: 4
• Pages: 687-691

Dates

published

2017

received

2017-07-28

revised

2017-10-26

accepted

2017-10-31

(unknown)

2017-12-05

Contributors

author

Roberta Ceci

• Università degli Studi di Roma "Foro Italico", Department of Movement, Human and Health Sciences, Unit of Biology, Genetics and Biochemistry, Rome, Italy

author

Guglielmo Duranti

• Università degli Studi di Roma "Foro Italico", Department of Movement, Human and Health Sciences, Unit of Biology, Genetics and Biochemistry, Rome, Italy

author

Paolo Sgrò

• Università degli Studi di Roma "Foro Italico", Department of Movement, Human and Health Sciences, Unit of Endocrinology, Rome, Italy

author

Stefania Sabatini

• Università degli Studi di Roma "Foro Italico", Department of Movement, Human and Health Sciences, Unit of Biology, Genetics and Biochemistry, Rome, Italy

author

Luigi Di Luigi

• Università degli Studi di Roma "Foro Italico", Department of Movement, Human and Health Sciences, Unit of Biology, Genetics and Biochemistry, Rome, Italy

References

• Aldridge J, Measham F (1999) Sildenafil (Viagra) is used as a recreational drug in England. Brit Med J 318: 669.
• Armani A, Marzolla V, Rosano GM, Fabbri A, Caprio M (2011) Phosphodiesterase type 5 (PDE5) in the adipocyte: a novel player in fat metabolism? Trends Endocrinol Metab 22: 404-411. doi: 10.1016/j.tem.2011.05.004.
• Aversa A, Fittipaldi S, Francomano D, Bimonte VM, Greco EA, Crescioli C, Di Luigi L, Lenzi A, Migliaccio S (2017) Tadalafil improves lean mass and endothelial function in nonobese men with mild ED/LUTS: in vivo and in vitro characterization. Endocrine 56: 639-648. doi: 10.1007/s12020-016-1208-y.
• Aversa A (2010) Systemic and metabolic effects of PDE5-inhibitor drugs. World J Diabetes 1: 3-7.
• Beavo JA, Brunton LL (2002) Cyclic nucleotide research - still expanding after half a century. Nat Rev Mol Cell Biol 3: 710–718.
• Bechara A, Casabe A, De Bonis W, Helien A, Bertolino MV (2010) Recreational use of phosphodiesterase type 5 inhibitors by healthy young men. J Sex Med 7: 3736-3742.
• Ceci R, Duranti G, Sgrò P, Sansone M, Guidetti L, Baldari C, Sabatini S, Di Luigi L (2015) Effects of tadalafil administration on plasma markers of exercise-induced muscle damage, IL6 and antioxidant status capacity. Eur J Appl Physiol 115: 531-539.
• Corbin JD, Francis SH (2002) Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 56: 453-459.
• Crescioli C, Sturli N, Sottili M, Bonini P, Lenzi A, Di Luigi L (2013) Insulin-like effect of the phosphodiesterase type 5 inhibitor tadalafil onto male human skeletal muscle cells. J Endocrinol Invest 36: 1020-1026. doi: 10.3275/9034.
• Dai Z, Wu Z, Yang Y, Wang J, Satterfield MC, Meininger CJ, Bazer FW, Wu G (2013) Nitric oxide and energy metabolism in mammals. Biofactors 39: 383-391. doi: 10.1002/biof.1099.
• Di Luigi L, Baldari C, Pigozzi F, Emerenziani GP, Gallotta MC, Iellamo F, Ciminelli E, Sgrò P, Romanelli F, Lenzi A, Guidetti L (2008) The long-acting phosphodiesterase inhibitor tadalafil does not influence athletes' VO2max, aerobic, and anaerobic thresholds in normoxia. Int J Sports Med 29: 110-115.
• Di Luigi L, Sgrò P, Baldari C, Gallotta MC, Emerenziani GP, Crescioli C, Bianchini S, Romanelli F, Lenzi A, Guidetti L (2012) The phosphodiesterases type 5 inhibitor tadalafil reduces the activation of the hypothalamus-pituitary-adrenal axis in men during cycle ergometric exercise. Am J Physiol Endocrinol Metab 302: E972-E978.
• Di Luigi L (2008) Supplements and the endocrine system in athletes. Clin Sports Med 27: 131-151.
• Duranti G, Ceci R, Sgrò P, Sabatini S, Di Luigi L (2017) Influence of the PDE5 inhibitor tadalafil on redox status and antioxidant defense system in C2C12 skeletal muscle cells. Cell Stress Chaperones 22: 389-396. doi: 10.1007/s12192-017-0778-9.
• Fiore D, Gianfrilli D, Giannetta E, Galea N, Panio G, di Dato C, Pofi R, Pozza C, Sbardella E, Carbone I, Naro F, Lenzi A, Venneri MA, Isidori AM (2016) PDE5 inhibition ameliorates visceral adiposity targeting the miR-22/SIRT1 pathway: evidence from the CECSID Trial. J Clin Endocrinol Metab 101: 1525-1534.
• Francis SH, Corbin JD (2003) Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Curr Urol Rep 4: 457-465.
• Frappier J, Toupin I, Levy JJ, Aubertin-Leheudre M, Karelis AD (2013) Energy expenditure during sexual activity in young healthy couples. PLoS One 8: e79342. doi: 10.1371/journal.pone.0079342.
• Grant RW, Stephens JM (2015) Fat in flames: influence of cytokines and pattern recognition receptors on adipocyte lipolysis. Am J Physiol Endocrinol Metab 309: E205-E213. doi: 10.1152/ajpendo.00053.2015.
• Guilherme A, Virbasius JV, Puri V, Czech MP (2008) Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 9: 367-377. doi: 10.1038/nrm2391.
• Jobgen WS, Fried SK, Fu WJ, Meininger CJ, Wu G (2006) Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates. J Nutr Biochem 17: 571-588.
• Koka S, Aluri HS, Xi L, Lesnefsky EJ, Kukreja RC (2014) Chronic inhibition of phosphodiesterase 5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: potential role of NO/SIRT1/PGC-1α signaling. Am J Physiol Heart Circ Physiol 306: H1558-H1568.
• Lafontan M, Moro C, Berlan M, Crampes F, Sengenes C, Galitzky J (2008) Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol Metab 19: 130-137. doi: 10.1016/j.tem.2007.11.006.
• Mammi C, Pastore D, Lombardo MF, Ferrelli F, Caprio M, Consoli C, Tesauro M, Gatta L, Fini M, Federici M, Sbraccia P, Donadel G, Bellia A, Rosano GM, Fabbri A, Lauro D (2011) Sildenafil reduces insulin-resistance in human endothelial cells. PLoS One 6: e14542. doi: 10.1371/journal.pone.0014542.
• Maneschi E, Cellai I, Aversa A, Mello T, Filippi S, Comeglio P, Bani D, Guasti D, Sarchielli E, Salvatore G, Morelli A, Mazzanti B, Corcetto F, Corno C, Francomano D, Galli A, Vannelli GB, Lenzi A, Mannucci E, Maggi M, Vignozzi L (2016) Tadalafil reduces visceral adipose tissue accumulation by promoting preadipocytes differentiation towards a metabolically healthy phenotype: Studies in rabbits. Mol Cell Endocrinol 424: 50-70. doi: 10.1016/j.mce.2016.01.015.
• Metzger IF, Sertorio JT, Tanus-Santos JE (2006) Relationship between systemic nitric oxide metabolites and cyclic GMP in healthy male volunteers. Acta Physiol (Oxf) 188: 123-127.
• Moro C, Lafontan M (2013) Natriuretic peptides and cGMP signaling control of energy homeostasis. Am J Physiol Heart Circ Physiol 304: H358-H368. doi: 10.1152/ajpheart.00704.2012.
• Sabatini S, Sgrò P, Duranti G, Ceci R, Di Luigi L (2011) Tadalafil alters energy metabolism in C2C12 skeletal muscle cells. Acta Biochim Polon 58: 237-241.
• Saponaro C, Gaggini M, Carli F, Gastaldelli A (2015) The subtle balance between lipolysis and lipogenesis: a critical point in metabolic homeostasis. Nutrients 7: 9453-9474. doi: 10.3390/nu7115475.
• Savary S, Trompier D, Andréoletti P, Le Borgne F, Demarquoy J, Lizard G (2012) Fatty acids - induced lipotoxicity and inflammation. Curr Drug Metab 13: 1358-1370.
• Sears B, Perry M (2015) The role of fatty acids in insulin resistance. Lipids Health Dis 14: 121. doi: 10.1186/s12944-015-0123-1.
• Venneri MA, Giannetta E, Panio G, De Gaetano R, Gianfrilli D, Pofi R, Masciarelli S, Fazi F, Pellegrini M, Lenzi A, Naro F, Isidori AM (2015) Chronic Inhibition of PDE5 limits pro-inflammatory monocyte-macrophage polarization in streptozotocin-induced diabetic mice. PLoS One 10: e0126580. doi: 10.1371/journal.pone.0126580.
• Vignozzi L, Gacci M, Cellai I, Santi R, Corona G, Morelli A, Rastrelli G, Comeglio P, Sebastanelli A, Maneschi E, Nesi G, De Nunzio C, Tubaro A, Mannucci E, Carini M, Maggi M (2013) Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate 73: 789-800. doi: 10.1002/pros.22623.
• Wolk R, Smith WB, Neutel JM, Rubino J, Xuan D, Mancuso J, Gilbert J, Pressler ML (2009) Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension. Hypertension 53: 1091-1097. doi: 10.1161/HYPERTENSIONAHA.109.132225.
• Zhang X, Ji J, Yan G, Wu J, Sun X, Shen J, Jiang H, Wang H (2010) Sildenafil promotes adipogenesis through a PKG pathway. Biochem Biophys Res Commun 396: 1054-1059. doi: 10.1016/j.bbrc.2010.05.064.

Identifiers

DOI

10.18388/abp.2017_2205